tradingkey.logo

Summit Therapeutics Inc <SMMT.OQ> expected to post a loss of 9 cents a share - Earnings Preview

ReutersApr 29, 2025 8:06 PM
  • Summit Therapeutics Inc SMMT.OQ SMMT.O is expected to show no change in quarterly revenue when it reports results on May 1 for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Summit Therapeutics Inc is for a loss of 9 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Summit Therapeutics Inc is $36.00​, above​ its last closing price of $24.11. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.08

-0.08

-0.08

Met

1.8

Sep. 30 2024

-0.06

-0.07

-0.08

Missed

-20

Jun. 30 2024

-0.06

-0.06

-0.09

Missed

-45.2​

Mar. 31 2024

-0.06

-0.06

-0.06

Met

0

​​

This summary was machine generated April 29 at 20:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI